Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | Improving outcomes for patients with metastatic NSCLC with immunotherapy

Mirjana Rajer • 8 Aug 2022
WCLC 2022
Lung Cancer Non-Small Cell Lung Cancer

Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, talks on the introduction of immunotherapy into the treatment landscape for patients with metastatic non-small cell lung cancer (NSCLC), and how this has improved patient outcomes. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

More from Mirjana Rajer

1:06
The unmet needs of palliative care in lung cancer
Mirjana Rajer • 8 Aug 2022
1:21
Common toxicities associated with checkpoint inhibitors in lung cancer and how to manage them
Mirjana Rajer • 8 Aug 2022
0:56
Checkpoint inhibitors for lung cancer treatment
Mirjana Rajer • 8 Aug 2022

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals